TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

What is the purpose of this trial?

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Participation Guidelines

Ages: 18 years and older

Gender: Male only

Clovis Oncology, Inc.

Start Date: 06/05/2018

End Date: 02/28/2022

Last Updated: 12/05/2018

Study HIC#: 2000020657